Molecular structure of Capecitabine, CAS Number: 154361-50-9
Capecitabine (CAS 154361-50-9)
See product citations (16)
Application:
Capecitabine is An antiproliferative 5-fluorouracil releasing compound
CAS Number:
154361-50-9
Purity:
≥98%
Molecular Weight:
359.35
Molecular Formula:
C15H22FN3O6
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Capecitabine may enzymatically converted to 5-fluorouracil (5-FU) in tumor cells. 5-FU is an antimetabolite that inhibits thymidylate synthase, leading to the depletion of thymidine triphosphate and the incorporation of fluorinated nucleotides into DNA and RNA. This disrupts DNA synthesis and repair, ultimately leading to cell death. 5-FU is incorporated into RNA, leading to the inhibition of protein synthesis. Capecitabine′s conversion to 5-FU occurs preferentially in tumor cells due to higher levels of thymidine phosphorylase, an enzyme involved in the conversion process.
Capecitabine (CAS 154361-50-9) References
- Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study. | Casadei Gardini, A., et al. 2017. Sci Rep. 7: 42499. PMID: 28211921
- Capecitabine Toxicity and Dihydropyrimidine Dehydrogenase Deficiency. | Tariq, Z., et al. 2018. Am J Ther. 25: e742-e743. PMID: 29889674
- A case of capecitabine-induced dermatomyositis. | Saraswat, N., et al. 2018. Indian J Pharmacol. 50: 350-353. PMID: 30783329
- Capecitabine and temozolomide combination for treatment of high-grade, well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma - retrospective analysis. | Rogowski, W., et al. 2019. Endokrynol Pol. 70: 313-317. PMID: 30843182
- Capecitabine versus 5-fluorouracil in neoadjuvant chemoradiotherapy of locally advanced rectal cancer: A meta-analysis. | Zhu, J., et al. 2019. Medicine (Baltimore). 98: e15241. PMID: 31027072
- Concomitant use of capecitabine and proton pump inhibitors - Is it safe? | Cheng, V., et al. 2019. J Oncol Pharm Pract. 25: 1705-1711. PMID: 31081468
- Silver nanoparticle/capecitabine for breast cancer cell treatment. | Hepokur, C., et al. 2019. Toxicol In Vitro. 61: 104600. PMID: 31302208
- Real-world outcomes for neoadjuvant capecitabine versus infusional 5-fluorouracil in the treatment of locally advanced rectal cancer. | Loft, M., et al. 2021. Intern Med J. 51: 1262-1268. PMID: 32896960
- The relationship between eGFR and capecitabine efficacy/toxicity in metastatic breast cancer. | Celik, E., et al. 2021. Med Oncol. 38: 11. PMID: 33452614
- Impact of Oral Chemotherapy Management Program on Capecitabine Toxicity Management. | Nhean, S., et al. 2021. JCO Oncol Pract. 17: e1021-e1029. PMID: 33900803
- Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma. | de Jong, EJM., et al. 2022. Int J Cancer. 150: 1654-1663. PMID: 34935139
- Assessment of Drug-drug Interaction and Optimization in Capecitabine and Irinotecan Combination Regimen using a Physiologically Based Pharmacokinetic Model. | Sakai, S., et al. 2022. J Pharm Sci. 111: 1522-1530. PMID: 34965386
- Cardiotoxicity from Capecitabine Chemotherapy: Prospective Study of Incidence at Rest and During Physical Exercise. | Lestuzzi, C., et al. 2022. Oncologist. 27: e158-e167. PMID: 35641220
Inhibitor of:
1700019N19Rik, AChRα, APOBEC2, Gastric Carcinoma Marker, HISPPD2A, Olr526, Olr690, and R2.Activator of:
1700019B03Rik, Gap 1, PD-ECGF, RFC-1, TFIIH p62, and UMPS.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Capecitabine, 250 mg | sc-205618 | 250 mg | $64.00 | |||
Capecitabine, 1 g | sc-205618A | 1 g | $208.00 | |||
Capecitabine, 5 g | sc-205618B | 5 g | $322.00 |